Introduction
This article serves as a formal correction (erratum) to the research paper titled "Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine‑induced hypo‑vascularization," which was originally published in the European Journal of Nuclear Medicine and Molecular Imaging in 2022. The primary objective of this notice is to ensure the accuracy of the academic record by rectifying an error in the institutional affiliation of one of the contributing authors.
Background of the Original Study
The original research (referenced as Eur J Nucl Med Mol Imaging (2022) 50:115–129) addressed a critical clinical challenge in oncology: the differentiation of various subgroups within Pancreatic Ductal Adenocarcinoma (PDAC). PDAC is known for its heterogeneity, which complicates treatment strategies and prognostic assessments.
The study investigated the utility of functional biomarkers derived from advanced medical imaging techniques, specifically Computed Tomography (CT) and Magnetic Resonance Imaging (MRI). A key focus of the research was identifying "hypo-vascularization"—a significant reduction in tumor blood supply—induced by the administration of the chemotherapy agent gemcitabine. By tracking these vascular changes, the researchers aimed to provide better tools for monitoring treatment response and understanding the physiological impact of chemotherapy on pancreatic tumors.
Details of the Correction
Following the publication of the original article, an administrative error was identified regarding the metadata of the research team. Specifically, the institutional affiliation for Dr. Hana Algül was listed incorrectly.
The corrected affiliation for Dr. Hana Algül is as follows: Comprehensive Cancer Center München, Chair for Tumor Metabolism, Klinikum rechts der Isar, Technical University of Munich, School of Medicine and Health, Munich, Bavaria, Germany.
This update ensures that Dr. Algül's contributions are correctly associated with the Technical University of Munich's Chair for Tumor Metabolism and the broader Comprehensive Cancer Center München.
Significance of Metadata Integrity
While this correction does not alter the scientific findings, data analysis, or conclusions of the original study, such errata are vital to the integrity of scientific publishing. Accurate author affiliations are essential for several reasons:
- Institutional Credit: Ensuring that the correct universities and research centers receive credit for the work produced by their faculty.
- Funding Accountability: Many research grants are tied to specific institutions; accurate metadata allows for the proper tracking of research output relative to funding sources.
- Academic Record: Maintaining a precise "version of record" is fundamental to the transparency and reliability of the global scientific database.
Conclusion
The scientific community is advised to note this change in affiliation for Dr. Hana Algül. The core findings of the 2022 study—regarding the use of CT and MRI biomarkers to categorize PDAC subgroups and the observation of gemcitabine-induced vascular changes—remain unchanged and valid as originally reported.
Summary updated